Pharma

Every rupee Indian insurers spend today on preventive health screenings saves them three to four rupees in claims tomorrow—a mathematical reality transforming how the nation approaches healthcare economics. As medical inflation gallops ahead at 13% in 2025, amongst Asia’s steepest rates, insurers and corporate health planners face an existential choice: continue absorbing spiralling hospitalisation costs […]

India’s digital health revolution presents a curious paradox: platforms like eSanjeevani have delivered over 340 million consultations by early 2025, transforming healthcare access for millions who previously faced hours-long queues or inaccessible specialists. Urban adoption soars past 60%, whilst tier-2 and tier-3 cities accelerate at over 20% compound annual growth rates, painting a picture of

A simple scan could be the difference between genuine medicine and a potentially lethal counterfeit. In chemist shops across India, a quiet revolution is unfolding on pharmacy shelves—every medicine package now carries a QR code that transforms patients from passive consumers into active participants in drug safety monitoring. Since August 2023, the Drugs Controller General

When European hospitals began rationing antibiotics and diabetics faced insulin shortages, the continent confronted an uncomfortable truth: its medicine supply chains had become dangerously fragile. Now, as the European Union prepares to implement its Critical Medicines Act—a sweeping legislative response to recurring drug shortages—an unexpected beneficiary emerges thousands of kilometres away. India’s pharmaceutical industry, already

Indian pharmaceutical manufacturing has long been synonymous with generic medicines and cost-effective healthcare solutions, but December 1, 2025, marked an inflection point that could redefine the industry’s global identity. When Wockhardt’s shares catapulted 19 per cent following a landmark US Food and Drug Administration approval, it wasn’t merely another market rally—it was a historic validation.

The global pharmaceutical landscape is witnessing a seismic shift, and Indian drugmakers are positioned at its epicentre. As the US biosimilars market prepares to quadruple from $22.6 billion in 2025 to a staggering $90 billion by 2034, a revolutionary FDA draft guideline has thrown open the gates for Indian manufacturers. By potentially halving development costs

Western sanctions were meant to isolate Russia—instead, they’ve opened the door for India. While European and American pharmaceutical companies retreat from the Russian market under pressure from their governments, Indian manufacturers are advancing, negotiating joint ventures, planning production facilities, and positioning themselves as the primary suppliers to a nation desperate for pharmaceutical self-sufficiency. Russia already